Meeder Asset Management Inc Rocket Pharmaceuticals, Inc. Transaction History

Meeder Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$20.66 - $26.72 $3,677 - $4,756	178 New	178 $3,000
Q4 2021 Feb 11, 2022	SELL	$21.52 - $36.02 $90,835 - $152,040	-4,221 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$27.42 - $48.97 $94,681 - $169,093	3,453 Added 449.61%	4,221 $127,000
Q2 2021 Aug 09, 2021	BUY	$39.41 - $47.25 $3,271 - $3,921	83 Added 12.12%	768 $34,000
Q1 2021 Apr 28, 2021	BUY	$43.34 - $65.91 $29,687 - $45,148	685 New	685 $30,000
Q4 2020 Feb 09, 2021	SELL	$23.3 - $59.57 $12,954 - $33,120	-556 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$20.5 - $28.59 $11,398 - $15,896	556 New	556 $12,000
Q2 2020 Aug 11, 2020	SELL	$13.32 - $22.61 $1,958 - $3,323	-147 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$9.71 - $25.11 $504 - $1,305	52 Added 54.74%	147 $2,000
Q4 2019 Feb 13, 2020	SELL	$11.07 - $24.23 $82,205 - $179,931	-7,426 Reduced 98.74%	95 $2,000
Q3 2019 Oct 17, 2019	BUY	$10.85 - $14.78 $81,602 - $111,160	7,521 New	7,521 $88,000

213

93.1M

319K

70.3K

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $851M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.